Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Get Free Report) Director David P. Southwell sold 10,000 shares of the stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $24.05, for a total transaction of $240,500.00. Following the completion of the transaction, the director now directly owns 114,784 shares of the company's stock, valued at $2,760,555.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Rocket Pharmaceuticals Price Performance
Shares of RCKT opened at $23.68 on Thursday. The stock has a fifty day moving average of $27.45 and a two-hundred day moving average of $25.27. The company has a current ratio of 7.80, a quick ratio of 7.80 and a debt-to-equity ratio of 0.04. Rocket Pharmaceuticals, Inc. has a fifty-two week low of $14.89 and a fifty-two week high of $32.53.
Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) last issued its quarterly earnings results on Monday, February 26th. The biotechnology company reported ($0.64) earnings per share for the quarter, beating the consensus estimate of ($0.78) by $0.14. During the same period last year, the company earned ($0.92) earnings per share. Equities research analysts forecast that Rocket Pharmaceuticals, Inc. will post -2.94 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Healthcare Takes A Big Step Forward With The Help Of AI
From The Bull Report | Ad
The average doctor can diagnose an illness correctly 50-90% of the time.
But one innovative company's medical AI gets it right 92%+.
Click here to see why this small company is trusted by the Mayo Clinic
Several institutional investors have recently bought and sold shares of RCKT. Wellington Management Group LLP raised its holdings in Rocket Pharmaceuticals by 56.0% in the 3rd quarter. Wellington Management Group LLP now owns 8,022,830 shares of the biotechnology company's stock valued at $164,388,000 after acquiring an additional 2,880,373 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Rocket Pharmaceuticals by 133.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,551,774 shares of the biotechnology company's stock valued at $24,612,000 after buying an additional 886,919 shares during the period. Maverick Capital Ltd. grew its stake in shares of Rocket Pharmaceuticals by 34.1% during the 4th quarter. Maverick Capital Ltd. now owns 3,395,818 shares of the biotechnology company's stock valued at $66,456,000 after buying an additional 863,452 shares during the period. State Street Corp grew its stake in shares of Rocket Pharmaceuticals by 33.8% during the 3rd quarter. State Street Corp now owns 3,392,333 shares of the biotechnology company's stock valued at $54,142,000 after buying an additional 856,076 shares during the period. Finally, Vanguard Group Inc. grew its stake in shares of Rocket Pharmaceuticals by 18.3% during the 4th quarter. Vanguard Group Inc. now owns 5,447,565 shares of the biotechnology company's stock valued at $163,264,000 after buying an additional 843,552 shares during the period. 98.39% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of research analysts have issued reports on the stock. UBS Group dropped their target price on shares of Rocket Pharmaceuticals from $56.00 to $54.00 and set a "buy" rating for the company in a report on Friday, March 1st. StockNews.com raised shares of Rocket Pharmaceuticals to a "sell" rating in a research note on Friday, February 9th. The Goldman Sachs Group began coverage on shares of Rocket Pharmaceuticals in a research note on Tuesday, April 2nd. They set a "neutral" rating and a $39.00 price objective for the company. Cantor Fitzgerald reissued an "overweight" rating and set a $65.00 price objective on shares of Rocket Pharmaceuticals in a research note on Tuesday, February 27th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Rocket Pharmaceuticals from $55.00 to $50.00 and set an "overweight" rating for the company in a research note on Tuesday, February 27th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, Rocket Pharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $52.13.
Get Our Latest Stock Report on Rocket Pharmaceuticals
Rocket Pharmaceuticals Company Profile
(
Get Free Report)
Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
